Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

A Clinically Relevant Androgen Receptor Mutation Confers Resistance to Second-Generation Antiandrogens Enzalutamide and ARN-509

18 Jun 2013

Abstract excerpt

UNLABELLED: Despite the impressive clinical activity of the second-generation antiandrogens enzalutamide and ARN-509 in patients with prostate cancer, acquired resistance invariably emerges. To identify the molecular mechanisms underlying acquired resistance, we developed and characterized cell lines resistant to ARN-509 and enzalutamide. In a subset of cell lines, ARN-509 and enzalutamide exhibit agonist...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Estrogen and related hormone effects
Share to Prostate Cancer Diagnosis and Treatment
Share to Prostate Cancer Treatment and Research

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 23779130
DOI: 10.1158/2159-8290.cd-13-0226

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

A Clinically Relevant Androgen Receptor Mutation Confers Resistance to Second-Generation Antiandrogens Enzalutamide and ARN-509PMID 23779130Read ↗

An F876L mutation in androgen receptor confers genetic and phenotypic resistance to MDV3100 (enzalutamide).Semantic proximity Read ↗

Resistance to second generation antiandrogens in prostate cancer: pathways and mechanismsSemantic proximity Read ↗

Overcoming mutation-based resistance to antiandrogens with rational drug design.Semantic proximity Read ↗

Androgen receptor targeting drugs in castration‐resistant prostate cancer and mechanisms of resistanceSemantic proximity Read ↗

Critical role of androgen receptor level in prostate cancer cell resistance to new generation antiandrogen enzalutamide.Semantic proximity Read ↗

Novel hormone therapies for advanced prostate cancer: Understanding and countering drug resistanceSemantic proximity Read ↗

Moving Towards Precision Urologic Oncology: Targeting Enzalutamide-resistant Prostate Cancer and Mutated Forms of the Androgen Receptor Using the Novel Inhibitor Darolutamide (ODM-201).Semantic proximity Read ↗

Identification of genes required for enzalutamide resistance in castration-resistant prostate cancer cells <i>in vitro</i>Semantic proximity Read ↗

Evaluation of Darolutamide (ODM201) Efficiency on Androgen Receptor Mutants Reported to Date in Prostate Cancer PatientsSemantic proximity Read ↗

Understanding and overcoming the mechanisms of primary and acquired resistance to abiraterone and enzalutamide in castration resistant prostate cancer.Semantic proximity Read ↗

Developing a Novel Enzalutamide-Resistant Prostate Cancer Model via AR F877L Mutation in LNCaP Cells.Semantic proximity Read ↗

Discovery of JNJ-63576253, a Next-Generation Androgen Receptor Antagonist Active Against Wild-Type and Clinically Relevant Ligand Binding Domain Mutations in Metastatic Castration-Resistant Prostate Cancer.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.